Skip to main content

Advertisement

Table 2 Adverse events

From: Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study

Organ system Total ATII Placebo P-value
Metabolic disorders 16 11 5  
Acidosis   2 3 1.00
Alkalosis   4 0 0.09
Blood or lymphatic disorders 7 3 4 1.00
Respiratory disorders 6 3 3 1.00
Worsening respiratory failure   1 3 0.58
Wheezing   1 0 1.00
Cardiac disorders 12 7 5 0.65
Hypertension1   2 0 0.58
Hypotension   2 1 1.00
Atrial fibrillation   2 0 0.47
Renal disorders2 7 6 2 0.17
Decreased urine output   3 1 0.58
Worsening acute kidney injury   0 2 0.47
Other disorders3 8 5 3 0.65
Worsening multiple organ system failure   2 3 1.00
  1. The results were presented as number of adverse events. 1Angiotensin II (ATII) infusion was discontinued in two patients due to hypertension. 2Of 20 patients 17 exhibited pre-existing acute kidney injury (AKI), including 8 patients receiving placebo and 9 patients receiving ATII. Of the three patients who did not have pre-existing AKI, one patient developed AKI and received ATII. 3Includes worsening multiple organ system failure, fever, lower extremity edema, and thigh hematoma. P-values were calculated using the Fisher exact test.